Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Numab Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option

              Contact the Supplier

              Lead Product(s): NM26-2198

              Therapeutic Area: Dermatology Product Name: NM26-2198

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kaken Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 13, 2021

              Details:

              Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.

              PharmaCompass__DigitalAd